Amy Mottl, MD, MPH, associate professor in the division of nephrology and hypertension, is receiving a five-year NIH Multi PI R01 grant award for “The Impact of Diabetes on Patients with Glomerular Disease: CureGN-Diabetes.”
IgA nephropathy (IgAN), focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), and membranous nephropathy (MN) are rare glomerular diseases that cause significant individual and societal morbidity. Diabetes mellitus is a common comorbidity of these glomerular diseases and may alter their diagnosis, treatment and long-term outcomes. CureGN-Diabetes is a longitudinal, observational ancillary study to CureGN (which does not include patients with diabetes), aimed at understanding and ameliorating the impact of diabetes on patients with glomerular diseases.
The aims of CureGN-GN Diabetes include: 1) To recruit and follow a multiethnic cohort of 300 adult patients with diabetes mellitus and biopsy documented IgAN, FSGS, MN, and MCD; 2) To assess the impact of diabetes on presenting features (clinical and histopathologic) and long- term outcomes in patients with IgAN, FSGS, MN, and MCD; AND 3) To identify individual and clusters of morphologic lesions which carry diagnostic and prognostic value. A strength of this study is the significant overlap between investigators and clinical sites involved in the CureGN and TRIDENT studies, which will expedite the efficiency and productivity emanating from this work. Furthermore, the CureGN-Diabetes Study will add to the available biorepositories of CureGN and TRIDENT, enriching the resources for future biomarker and mechanistic studies of primary glomerular disease versus diabetes-mediated pathways.
Other principal investigators include Andy Bomback, MD (Columbia University), Jonathan Hogan, MD (University of Pennsylvania School of Medicine) and Cynthia Nast, MD (Cedars-Sinai Medical Center).